PYOTT DAVID E I 4

What Happened

• David E. Pyott, a director of Tarsus Pharmaceuticals, had 1,383 restricted stock units (RSUs) vest and be settled into 1,383 shares of common stock on April 24, 2026. The Form 4 records the conversion/acquisition of 1,383 shares and a corresponding derivative disposition entry showing a $0.00 price. No cash purchase or open-market sale is reported in the filing.

Key Details

• Transaction date: April 24, 2026.
• Acquisition: 1,383 shares issued upon settlement of vested RSUs (price N/A).
• Disposition entry: 1,383 shares recorded at $0.00 (derivative conversion entry per filing).
• Footnotes: RSUs represent a contingent right to one share each; the RSUs vested in full on April 24, 2026, subject to continuous service (Footnotes F1–F3).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Filing accession date: April 28, 2026 (no timeliness flag provided in the excerpt).

Context

• This was an RSU settlement (award vesting and conversion to common stock), a common form of equity compensation for directors and executives; it is not an open-market purchase or sale. The derivative entries reflect the conversion/settlement mechanics rather than a cash transaction. Such vesting events typically reflect compensation vesting schedules rather than a direct signal of insider buying or selling intent.